GLP-1 market heats up as companies vie for next-gen obesity drugs
Oct 31, 2024 · Since the FDA approval of Novo Nordisk’s Wegovy as a treatment for chronic weight management in 2021, followed by the approval of Ozempic the next year, demand for GLP-1 agonist drugs has rapidly grown.
Vetter Pharma International
Vetter is a leading global contract development and manufacturing organization (CDMO) for the aseptic production of injectables. Our headquarters are in Ravensburg, Germany, where we have been a family-owned company since our start as a pharmacy in 1950.
Pharmaceutical Supply, Pharmaceutical Manufacturing, Contract …
4 days ago · Daily news on pharmaceutical outsourcing. Free access to news on pharmaceutical supply, pharmaceutical manufacturing, contract research and pharmaceutical services
APIs: high-volume business with low profit margins, says analyst
Jul 12, 2016 · Demand is particularity high in low- and middle-income countries in the Asia Pacific, Africa and Latin America. “This increased demand fueled the surge of API manufacturers, as pharmaceutical drug manufacturers do not have enough in-house capacity to meet the enormous market demand,” said Goel. With this increased demand, several API manufacturers have come under scrutiny lately for ...
Novocure's TTFields therapy boosts survival in pancreatic cancer
Dec 3, 2024 · Swiss oncology specialist Novocure has announced positive topline results from the PANOVA-3 phase 3 clinical trial, which evaluated the use of tumor treating fields (TTFields) therapy in combination with the chemotherapy drugs gemcitabine and nab-paclitaxel.
Veeva’s Tim Davis on overcoming eCOA deployment challenges
Nov 6, 2024 · Tim Davis, vice president of strategy at Veeva eCOA, had a conversation with Outsourcing Pharma's senior editor, Liza Laws, and sheds light on how the landscape is changing and what this means for study teams, sites, and overall trial efficiency.
Merck acquires Modifi Biosciences in $1.3B cancer drug deal
Oct 24, 2024 · Modifi Biosciences, a spin out of Yale University founded in 2021, has been snapped up by Merck for $30 million paid upfront, and up to $1.3 billion in potential milestone payments.
$680M deal with CBC and Mubadala shifts UCB's strategy
Aug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company.
Drug delivery news round up featuring Amylin, Zogenix, and more
Jun 6, 2012 · Bruce Redding Jr, CEO of Transdermal Specialties, said: “We believe the technology has the potential to increase the number of pharmaceuticals which may be delivered transdermally from a number less than 20 currently expanding past the 175 formulations already modelled by Transdermal Specialties.” Zogenix has submitted an investigational new drug (IND) application to the FDA for a ...
Equity boost and partnership aim to accelerate GEMS platform's …
Nov 15, 2024 · NVentures also participated in the company’s $200 million Series B last August. This strengthened collaboration is aimed at advancing Genesis' capabilities to tackle complex and previously undruggable disease targets through optimized AI technologies.The collaboration centers on advancing Genesis’ computational efficiency, with NVIDIA bringing specialized expertise to enhance the GEMS ...